With a broad experience in developing drug delivery devices, our multidisciplinary team has a deep knowledge of a variety device types and how to effectively deliver sensitive biologics, and small molecules. We have specific expertise in ophthalmic drug delivery, soft mist inhalers (having worked for Boehringer Ingelheim on the Respimat) and on generic competitors, and delivering cell and gene therapies.
We deliver all of the device development phases or can work on specific phases individually as required. We can also provide technology scouting, root cause analysis, problem solving, due diligence, expert review, and device portfolio strategy management.
Many of our clients are multinational pharmaceutical companies or major medical device manufacturers. They often think of us as their device development group, and we build strong strategic relationships across multiple devices and platforms.
We work on full device development projects, as well as problem solving and risk analysis of devices already in development or on the market to reduce risk, and minimise cost.
Springboard has a breadth of experience in the design and development of devices across the inhalation field including:
- Dry powder inhalers (DPIs)
- Soft mist inhalers (SMIs)
- Pressurised metered dose inhalers (pMDIs)
- Nasal inhalers
Our end-to-end experience in developing transdermal drug delivery devices helps clients to get their device to market.
We have a wealth of expertise in the design and development of stationary and ambulatory infusion pumps, and can also provide valuable insights into how novel infusion technologies can break into the field.
ISO 13485 Certified
All of our projects are managed with an ISO 13485 certified quality system, so quality is a habit for our team.
Our Quality Management System allows us to customise processes to fit our clients’ internal systems.